PORTLAND, Ore.--(BUSINESS WIRE)--AVI BioPharma, Inc. (Nasdaq:AVII), today announced dosing of the first patient in a proof-of-principle clinical trial using AVI-4658, AVI’s lead drug candidate for Duchenne muscular dystrophy (DMD), based on the company’s proprietary ESPRIT (Exon Skipping Pre-RNA Interference Technology) drug platform.
